Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast)|Malignant Ascites
Interventions: BIOLOGICAL: Catumaxomab (Removab)|PROCEDURE: paracentesis
Sponsor: Neovii Biotech